Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020
April 05, 2021 at 05:16 pm EDT
Share
Rasna Therapeutics, Inc. announced earnings results for the first quarter ended December 31, 2020. For the first quarter, the company announced operating loss was USD 154,941 compared to USD 149,281 a year ago. Net loss was USD 171,862 compared to USD 158,042 a year ago.
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
ACTAVIA LIFE SCIENCES, INC. 
